SecBot SecBot
8-K ·Filed Nov 13, 2026

RVTY

REVVITY, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 16h ago SEC0001628280-26-073578
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor Q4 2026 earnings call for formal 2027 guidance. The LRP targets are aspirational and depend on market normalization; watch for execution on Signals Software SaaS penetration growth and Immunodiagnostics geographic expansion as leading indicators.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$154.39
T+0 close · Nov 13, 2026 · via day close
Latest settled
−3.59%
T+1 · $148.85
Vs SPY
−1.68%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $154.39entry
  2. T+1 · 17h ago −3.59%α −1.68% · $148.85
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revvity held its 2026 Investor Day, presenting its long-range financial outlook with 6-8% organic revenue growth (200bps above market), double-digit adjusted EPS growth, and 75bps annual operating margin expansion. The company provided segment-level LRP organic growth targets: Life Sciences Solutions 6-8%, Immunodiagnostics 7-9%, Reproductive Health 3-5%, and Signals Software 10-12% APV. 2027 considerations include ~6% organic growth, ~$85M net interest, ~19% tax rate, and flat share count.

Key Facts

  • 2026E revenue ~$2.9B, with ~55% Life Sciences and ~45% Diagnostics
  • LRP organic growth targets: Life Sciences Solutions 6-8%, Immunodiagnostics 7-9%, Reproductive Health 3-5%, Signals Software 10-12% APV
  • Long-term financial outlook: 6-8% organic revenue growth (200bps above market), double-digit adjusted EPS growth, 75bps annual operating margin expansion
  • 2027 considerations: ~6% organic growth, ~200bps above market, ~20bps additional operating leverage, net interest ~$85M, tax rate ~19%, flat share count
  • Signals Software metrics: 2026E ARR >$275M (13% CAGR from 2020), APV >$130M (47% CAGR), SaaS penetration ~35% (40% CAGR), net retention rate ~107% historical average
  • Adj. operating margin ~28.8% for 2026E, with target of mid-30s% over time
  • Since 2022: adj. EPS grew from ~$2B to ~$5.43 (2026E), free cash flow >$575M with >90% FCF conversion, 12% reduction in share count
  • ~$5B of capital capacity through 2031 with commitment to investment-grade credit rating
  • Diagnostics segment LRP organic growth: 5-7% (Immunodiagnostics 7-9%, Reproductive Health 3-5%)
  • Life Sciences segment LRP organic growth: 7-9% (Life Sciences Solutions 6-8%, Signals Software 10-12% APV)

Financial Impact

Long-range plan targets 6-8% organic revenue growth with double-digit adjusted EPS growth and 75bps annual margin expansion; 2027 guided ~6% organic growth

revenueepsoperating marginfree cash flow

Risk Factors

  • Forward-looking statements are aspirational and subject to market conditions, pharma/biotech spending, and geopolitical uncertainty
  • Life Sciences Solutions segment has been flat (CAGR since becoming Revvity) and needs market normalization to achieve 6-8% LRP growth
  • Reproductive Health faces birth rate headwind of -200bps, partially offset by menu expansion and geographic growth
  • Immunodiagnostics China business under definitive agreement to be divested, creating uncertainty

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
44% bullish (25 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-073578
Document: pki-20261113.htm0001628280-26-073578
Document: a2026investordaypressrelea.htm0001628280-26-073578
Document: 0001628280-26-073578-index-headers.html0001628280-26-073578
Document: 0001628280-26-073578-index.html0001628280-26-073578
Document: 0001628280-26-073578.txt0001628280-26-073578

Track record

9 reports on RVTY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.31% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.85 −1.28% settles Dec 15
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Viewing Entry $154.39 Now $148.85 −3.59% settles Dec 14
  3. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $163.48 Now $148.85 −8.95% settles Dec 2
  4. Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.85 −3.74% ▲ +2.33% +3.75% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.85 −3.09% ▲ +3.80% +5.13% vs SPY
  6. Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.85 +1.17% ▼ −4.43% −4.85% vs SPY
  7. Aug 4, 202614w ago 8-K Bullish 7/10 Entry $111.39 to $126.59 Now $148.85 +33.63% ▲ +13.65% +14.88% vs SPY
  8. May 5, 202627w ago 8-K Mixed 5/10 Entry $92.30 to $100.39 Now $148.85 +61.27% ▲ +8.76% +3.81% vs SPY
  9. Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.85 +72.26% ▲ +8.13% +4.35% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026